Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment.
Christophe BarbaMarion PeyreLionel GalicierPascal CathebrasDana RantaSandrine MalotAgnès VeyradierPaul CoppoPublished in: British journal of haematology (2020)